Page 11 - Flipbook
P. 11
ARAT Retreatment and Switching to an Agent with a Different
Mechanism of Action Are Options
• Non-hormonal treatments may be Cabazitaxel vs anti-androgen (CARD) *
1
preferred after use of ARAT 1
100
HR: 0.64 (95% CI, 0.46-0.89)
• In the Phase IV CARD study, cabazitaxel was 80 P=0.008
superior to an ARAT in third-line mCRPC 60
previously treated with docetaxel and a Probability OS (%)
1
different ARAT * 40
20
• Phase 3 PROfound study of olaparib
provides additional evidence for this 0
0 10 20 30 40
concept 2 Time (months)
Cabazitaxel Enzalutamide or abiraterone
*Study of 255 patients with mCRPC who had previously received docetaxel and an ARAT (abiraterone or enzalutamide)
ARAT, androgen receptor-axis-targeted therapies; mCRPC, metastatic castration-resistant prostate cancer
1. de Wit R et al. NEJM 2019;381:2506-18. 2. de Bono J et al. NEJM 2020;382:2091-102.
